tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Hiraoka Y et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. 1992 J. Pharmacol. Exp. Ther. pmid:1372051
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Morisaki M and Arai T Identity of immunosuppressant FR-900520 with ascomycin. 1992 J. Antibiot. pmid:1372308
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Demetris AJ et al. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. 1992 Lancet pmid:1376851
Ichihashi T et al. Haemolytic uraemic syndrome during FK506 therapy. 1992 Lancet pmid:1376852
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Karpas A et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1381509
Yatscoff RW and Shaw LM Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. 1992 Ther Drug Monit pmid:1381530
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Cryan J et al. FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. 1991 Biochem. Biophys. Res. Commun. pmid:1719972
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Karlsson H et al. The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. 1991 Immunol. Lett. pmid:1720417
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Ringe D Immunosuppression. Binding by design. 1991 Nature pmid:1710317
Tropschug M and Hofmann R FK506 and protein kinase C. 1991 Nature pmid:1710319
Granelli-Piperno A and McHugh P Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1722332
Nelson PA et al. cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. 1991 Gene pmid:1722474
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649